In a collaborative effort Heinz Läubli and co-workers have identified a new potential target to improve T cell activation in immunotherapy.
The researchers focused on the sialoglycan-SAMP/Siglec pathway, in particular on Siglec-9, an inhibitory receptor that is expressed on a broad range of immune cells on which it recognizes sialic acids expressed by tumors. They demonstrate…
